Publications by authors named "F Losa"
Article Synopsis
- The CUPISCO trial is studying whether a new treatment approach called molecularly guided therapy (MGT) can help patients with a type of cancer called cancer of unknown primary (CUP) do better than the standard chemotherapy.
- This trial involved 1,505 patients from 34 countries and focused on those who showed improvement after initial chemotherapy.
- The goal is to see if using genomic profiling in deciding treatments can lead to better results in fighting cancer compared to the usual treatment options.
Metastatic colorectal cancer (mCRC) currently lacks reliable biomarkers for precision medicine, particularly for chemotherapy-based treatments. This study examines the behavior of 11 CXC chemokines in the blood of 104 mCRC patients undergoing first-line oxaliplatin-based treatment to pinpoint predictive and prognostic markers. Serum samples were collected before treatment, at response evaluation (EVAR), and at disease progression or last follow-up.
View Article and Find Full Text PDFBackground: Patients with unfavorable carcinoma of unknown primary origin (CUP) have an extremely poor prognosis of ∼1 year or less, stressing the need for more tailored treatments, which are currently being tested in clinical trials. CUPISCO (NCT03498521) was a phase II randomized study of targeted therapy/cancer immunotherapy versus platinum-based chemotherapy in patients with previously untreated, unfavorable CUP, defined as per the European Society for Medical Oncology guidelines. We present a preliminary, descriptive molecular analysis of 464 patients with stringently diagnosed, unfavorable CUP enrolled in the CUPISCO study.
View Article and Find Full Text PDFArticle Synopsis
- - The study analyzed the long-term effectiveness of mepolizumab in severe asthma patients, focusing on reducing exacerbations and steroid dependence over three years.
- - Results showed a significant decrease in exacerbations from 84.6% in the first year to 90% and 95% in the subsequent years, along with a reduction in steroid dependency from 54% to just 6%.
- - Additionally, patients with nasal polyps experienced a 49% decrease in symptoms measured by the SNOT-22 scale, confirming mepolizumab's long-term benefits in an actual clinical setting.
Background: The results of the Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)-1402 phase II randomized trial suggested that adding aflibercept to modified fluorouracil, oxaliplatin, and leucovorin (mFOLFOX6) induction, followed by chemoradiation and surgery, could increase the pathological complete response (pCR) rate in patients with high-risk, locally advanced rectal cancer. Here we update results up to 3 years of follow-up and evaluate the predictive value of consensus molecular subtypes identified with immunohistochemistry (IHC).
Methods: Patients with magnetic resonance imaging-defined T3c-d and/or T4 and/or N2 rectal adenocarcinoma in the middle or distal third were randomly assigned to mFOLFOX6 induction, with aflibercept (mF+A; n = 115) or without aflibercept (mF; n = 65), followed by capecitabine plus radiotherapy and surgery.